Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Admetsys
AddedFeb 17, 2024
UpdatedJul 17, 2026
Admetsys

Admetsys

Angel

Admetsys: A biomedical tech firm pioneering an artificial pancreas for hospital care with proven success.

HQ
Boston, NY, US
Founded
2010
Overview
Compare
Fundraising
Employees
Website

Admetsys, founded with a mission to revolutionize hospital and surgical care, is a biomedical technology company that has developed an innovative artificial pancreas. This system leverages adaptive learning algorithms to manage insulin and glucose levels, providing high-precision automation tailored to individual patients. Their core products include the PrecisionOne™ clinical automation controller and the Intravenous Laboratory™ for real-time continuous blood diagnostics, focusing on critical care and surgery markets.

Notable achievements for Admetsys include three successful FDA-approved clinical trials demonstrating 97% control of blood glucose levels between 80–125 mg/dl with zero incidents of hypoglycemia. The company's impact is significant in enhancing patient outcomes through automated, precise metabolic control, positioning it as a leader in clinical robotics and critical care innovation.

Admetsys - Similar Companies

Beta Bionics logo

Beta Bionics

Monarch Medical Technologies logo

Monarch Medical Technologies

monarchmedtech.com

Ideal Medical Technologies logo

Ideal Medical Technologies

idealmedtech.com

Bigfoot Biomedical logo

Bigfoot Biomedical

Insulet logo

Insulet

insulet.com

Tandem Diabetes Care logo

Tandem Diabetes Care

tandemdiabetes.com

Admittance Technologies logo

Admittance Technologies

Autonomous Healthcare logo

Autonomous Healthcare

Hygieia logo

Hygieia

hygieia.com

Diatech Diabetes logo

Diatech Diabetes

AdaptX logo

AdaptX

adaptx.com

Glycostasis logo

Glycostasis

ADM Diagnostics logo

ADM Diagnostics

admdx.com

Dexcom logo

Dexcom

dexcom.com

Glytec logo

Glytec

glytec.com

Admetsys - Quick Facts

Who are Admetsys' competitors?

Companies similar to Admetsys include Beta Bionics, Monarch Medical Technologies, Ideal Medical Technologies and Bigfoot Biomedical.

When was Admetsys founded?

Admetsys was founded in 2010.

Where is Admetsys' headquarters located?

Admetsys' headquarters is located in Boston, NY, US.

When was Admetsys' last funding round?

Admetsys' most recent funding round was for $35k (USD) in May 2018.

How much has Admetsys raised to-date?

As of May 16, 2018, Admetsys has raised a total of $35k (USD).

How many employees does Admetsys have?

Admetsys has 5 employees as of Feb 4, 2024.

Admetsys - Classification

Industry
  • Hardware
Ownership
  • Equity
  • Venture Capital
Technology
  • AI
  • Machine Learning
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Artificial Pancreas
  • Medical Devices
Tags
  • Biotech
  • Healthtech
  • Hospital
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
Show 9 more industry codes
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 623000Nursing and Residential Care Facilities
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research